ERBB2 and breast cancer: Moreover, no statistically significant differences were observed in the expression of ER, PR, HER2, and Ki-67 in the primary breast cancer foci and recurrence and metastasis foci; the total change rates of ER, PR, HER2, and Ki-67 were 47.69%, 51.54%, 28.10%, and 29.23%, respectively.